Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegylated interferon alfa plus tenofovir versus either agent alone in HBeAg-negative chronic hepatitis B
IRCT20181113041635N1Phase 3Completed
- Sponsor
- Iran National Science Foundation
- Start
- Sep 2015
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pegylated interferon alpha and tenofovir in Chronic Hepatitis B (CHB) (3 arms), sponsored by Iran National Science Foundation. Primary endpoint: ALT normalization and HBV DNA suppression at week 48. Started Sep 2015; status: completed.
02
Drugs
pegylated interferon alphatenofovir
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on IRCT20181113041635N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20181113041635N1.